INTRACRANIAL PROGRESSION-FREE SURVIVAL AND PROGNOSTIC FACTORS OF BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER TREATED WITH GAMMA KNIFE RADIOSURGERY AND TYROSINE KINASE INHIBITORS
Nội dung chính của bài viết
Tóm tắt
Objectives: To investigate intracranial progression-free survival (iPFS) and its associated prognostic factors in patients with brain metastases (BM) from non-small cell lung cancer (NSCLC) treated with a combination of upfront Gamma Knife radiosurgery and tyrosine kinase inhibitors (TKIs). Methods: A longitudinal observational study was conducted on 74 patients at Vietnam National Cancer Hospital from February 2021 to May 2025. Results: The median iPFS was 22 months (95%CI: 17.45 - 26.55). The iPFS rates at 6, 12, and 24 months were 94.6%, 77.9%, and 40.4%, respectively. Regression analysis revealed that iPFS was not significantly influenced by the number of BM (p = 0.98), total tumor volume (p = 0.51), EGFR mutations (p = 0.26). In contrast, the presence of extracranial metastases (HR: 3.39, 95%CI: 1.31 - 8.74; p = 0.01) and the status of extracranial disease control (HR: 4.52; 95%CI: 2.13 - 9.60, p < 0.01) were identified as two independent prognostic factors for iPFS. Conclusion: In this study, the median iPFS was 22 months for NSCLC patients with BM treated with upfront Gamma Knife and TKIs. The presence of extracranial metastases and poorly controlled extracranial disease were significant predictors of iPFS.
Từ khóa
Non-small cell lung cancer, Brain metastases, Intracranial progression-free survival, Gamma Knife radiosurgery, Tyrosine kinase inhibitors
Chi tiết bài viết
Tài liệu tham khảo
2. Magnuson WJ, Lester-Coll NH, Wu AJ, et al . Management of BM in tyrosine kinase inhibitor-naïve epidermal growth factor receptor-mutant non-small-cell lung cancer: A retrospective multi-institutional analysis. Journal of Clinical Oncology. 2017; 35(10):1070-1077.
2. Nguyễn Văn Kiên, Phạm Cẩm Phương, Nguyễn Thị Phương Thảo. Đánh giá kết quả điều trị ung thư phổi không tế bào nhỏ di căn não có đột biến EGFR bằng thuốc ức chế tyrosine kinase kết hợp xạ phẫu dao Gamma quay tại Bệnh viện Bạch Mai. Tạp chí Y học Việt Nam. 2021; 506 (2):255-260.
3. Chiou GY, Chiang CL, Yang HC, et al. Combined stereotactic radiosurgery and tyrosine kinase inhibitor therapy versus tyrosine kinase inhibitor therapy alone for the treatment of non-small cell lung cancer patients with BM. Journal of Neurosurgery. 2021; 1(aop):1-8.
4. Lee CC, Hsu SPC, Lin CJ, et al. Epidermal growth factor receptor mutations: association with favorable local tumor control following Gamma Knife radiosurgery in patients with non-small cell lung cancer and BM. J Neurosurg. 2020; 133 (2):313-320.
5. Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple BM (JLGK0901): A multi-institutional prospective observational study. Lancet Oncol. 2014; 15(4):387-395.
6. Serizawa T, Yamamoto M, Higuchi Y, et al. Local tumor progression treated with Gamma Knife radiosurgery: differences between patients with 2 - 4 versus 5 - 10 BM based on an update of a multi-institutional prospective observational study (JLGK0901). J Neurosurg. 2020; 132(5):1480-1489.
7. Zhao X, Ding S, Zhang M, et al. Gamma knife radiosurgery for patients with BM from non-small cell lung cancer: Comparison of survival between < 5 and ≥ 5 metastases. Thorac Cancer. 2022; 13(15):2152-2157.
8. Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015; 16(7):830-838.
9. Tozuka T, Noro R, Mizutani H, et al. Osimertinib plus local treatment for BM versus osimertinib alone in patients with EGFR-mutant non-small cell lung cancer. Lung cancer. 2024; 191:107540.